Releases - DiaGenic ASA

View:
 

Found press releases

 

Annual General Meeting held

5/23/2013 5:31 AM EST
The annual general meeting of DiaGenic ASA was held on 23 May 2013.

All proposals set out in the notice to the general meeting were
approved.

In accordance with the recommendation from the Nomination Committee
Hanne Skaarberg Holen was elected as Chairman of the board, and Patrik
Dahlen, Ulrica Slåne and Tom Pike were elected as members of the board.

Leif Eriksrød (Alfred Berg Kapitalforvaltning) was elected as...

Proposal from the nomination committee

5/16/2013 3:40 AM EST
Please find attached the proposal from the nomination committee in
DiaGenic ASA to the Company's General Meeting on 23 May 2013.
Contact:

Paul de Potocki, Chief Executive Officer

Telephone: 47 2324 8950

e-mail:  
About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to
create value for patients, partners and investors by developing
innovative and patient...

Report from first quarter 2013

5/15/2013 1:59 AM EST
Private placement raising NOK 30 million completed, full focus on
Alzheimer's disease product portfolio development
The interim report for the first quarter 2013 was approved by the Board
of Directors on 14 May 2013. Please find the interim report and
presentation attached.
Highlights from the report:

· On 7 March 2013 DiaGenic raised NOK 30 million in gross proceeds
through a private placement of 50 million new...

Presentation of results for first quarter 2013

5/14/2013 2:23 AM EST
DiaGenic will present results for the first quarter 2013 on Wednesday 15
May 2013. Interim report and presentation slides will be posted on
www.newsweb.no and on DiaGenic's web page: www.diagenic.com on 15 May at
approximately 08:00 CET.

A conference call for a presentation of the results is scheduled the
same day at 12:00 CET. Please use the dial-in details listed below,
corresponding to your location, to...

Increase in share capital

5/8/2013 3:23 AM EST
Oslo, 8 2013

Reference is made to the stock exchange announcement from DiaGenic ASA
(the "Company") dated 29 April 2013 regarding the result in the
subsequent repair offering.

The share capital increase pertaining to the subsequent offering has now
been registered with the Norwegian Register of Business Enterprises. The
new registered share capital of DiaGenic is NOK 40,799,365 divided into
81,598,730 shares, each...

Notice of Annual General Meeting in DiaGenic ASA

5/2/2013 4:00 AM EST
The board of directors of DiaGenic ASA (the "Company") hereby convenes
the annual general meeting for 2013.

Time:   23 May 2013 at 10:00 hours (CET)

Place:   Grenseveien 92, Oslo, Norway

Agenda:

1. Opening of the meeting by chairman of the board Henrik Lund,
including registration of shareholders present
2. Election of chairman of the meeting and a person to co-sign the
minutes
3. Approval of notice and...

FINAL RESULT IN THE SUBSEQUENT REPAIR OFFERING

4/29/2013 1:26 PM EST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE
UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT
NOTICE AT THE END OF THIS STOCK EXCHANGE NOTICE.
Oslo, 29 April 2013

Reference is made to DiaGenic ASA's (the "Company") prospectus dated 5
April...

PRELIMINARY RESULT IN THE SUBSEQUENT REPAIR OFFERING

4/24/2013 2:26 AM EST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE
UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT
NOTICE AT THE END OF THIS STOCK EXCHANGE NOTICE.
Oslo, 24 April 2013

Reference is made to the stock exchange notices published by DiaGenic
ASA (the...

EXPIRY OF SUBSCRIPTION PERIOD AND LAST TRADING DAY FOR SUBSCRIPTION RIGHTS IN TH...

4/23/2013 2:00 AM EST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE
UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT
NOTICE AT THE END OF THIS STOCK EXCHANGE NOTICE.
Oslo, 23 April 2013

Reference is made to the stock exchange notice published by DiaGenic ASA
(the...

DiaGenic patent allowed in Canada

4/11/2013 5:01 AM EST
DiaGenic has received notice of allowance for its Canadian family 2
patent application. The allowed claims cover the use of a set of gene
sequences in blood essential for the diagnosis of, among other diseases,
Alzheimer's disease and stages thereof. The patent when granted will be
valid until 2023.
Contact:

Paul de Potocki, Chief Executive Officer

Telephone: 47 2324 8950

e-mail:  
About...

DiaGenic ASA

RSS